Rich HCC clinical pipeline can lead to $3.8 billion sales by 2027 for G8

8 October 2018

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and, also a leading cause of cancer-related deaths worldwide.

The incidence and subsequent mortality of the disease is on a continuous upsurge despite gradually improving screening, diagnosis, and treatment. The disease is found to be more common in males as compared to females, according to a new report, " Hepatocellular Carcinoma (HCC) Market Insights, Epidemiology and Market Forecast-2027" added to the offering of DelveInsight.

According to the DelveInsight report, the total incident cases of HCC in the G8 countries, ie, the USA, EU5 (Germany, France, Italy, Spain and the UK), Japan and China, were found to be 458, 170 in 2016, while the corresponding diagnosed advanced HCC cases in the G8 countries were found to be 160,565 for the same year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK